Jason Snipe is an investment management executive and portfolio strategist with extensive experience advising high-net-worth individuals, entrepreneurs, and institutional clients. He specializes in portfolio construction, long-term asset allocation, and disciplined investment strategy.

He is the Founder and Chief Investment Officer of Odyssey Capital Advisors, an independent investment management firm based in the Philadelphia area. In this role, he leads the construction and oversight of the firm’s flagship portfolios in partnership with its internal investment committee, guiding investment strategy and risk management across client accounts. Previously, he served as a Partner and investment advisor at First Genesis Financial Group, where he advised executives, entrepreneurs, and institutional clients on tailored investment strategies. He has been recognized for excellence in wealth management, including being named a Top 40 Under 40 Wealth Manager by Fortune in 2020 and a Five Star Wealth Manager by Philadelphia Magazine from 2012–2020.

Mr. Snipe is a contributor to CNBC, where he provides expert commentary on markets, investing, and financial strategy. He also serves as Executive in Residence at Lane College, where he works to advance financial vitality and bring real-world investment expertise to the institution’s community.

Mr. Snipe earned a B.S. in Economics from Villanova University. He and his family are active supporters of Breakthrough T1D (formerly JDRF), and he serves as Vice Chair of the Board of Trustees at LaSalle Academy. He currently sits on the Capital Committee and is a strategic advisor to the T1D Fund.

Teri Foy, PhD, is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in oncology and inflammation. Her work has focused on advancing immune-based therapies from discovery through clinical translation, spanning cancer and autoimmune disease.

Most recently, she served at Bristol Myers Squibb, where she led the Immuno-Oncology and Cell Therapy Thematic Research Center. In this role, she guided early immuno-oncology and cell therapy programs from discovery through human proof of concept, advancing immune-based biologics and cell therapies across hematologic and solid tumors as well as autoimmune disease. She also built and led cross-functional teams and cultivated strong internal and external scientific collaborations to accelerate pipeline development. Prior to BMS, she spent more than five years at Celgene, helping establish the company’s Seattle site and playing a central role in shaping its immuno-oncology strategy and pipeline. Earlier in her career, she held scientific leadership roles at Corixa and GlaxoSmithKline, and served as Chief Scientific Officer at VLST.

Dr. Foy earned her Ph.D. in Immunology from the University of Iowa, an M.S. in Microbiology, and completed a postdoctoral fellowship in Immunology at Dartmouth Medical School. She has an extensive publication record and holds nearly a dozen patents covering novel immune compositions. She currently serves as a Strategic Advisor to the T1D Fund.